Table of Contents
Volume 2 | Issue 4
Publication Date: March 2004- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Editorial | ||
200-201 |
Current Status of Prostate Cancer Management in the Prostate-Specific Antigen Era Oliver Sartor |
|
Researches in Brief | ||
202-205 |
The Development of Vitamin D–Based Therapies for Prostate Cancer Nancy Price, Amy D’Orazio, Vinay K. Jain, Oliver Sartor |
|
206-208 |
Finasteride, a Selective 5-Alpha-Reductase Inhibitor, in the Prevention and Treatment of Human Prostate Cancer G. Kesava Reddy, Oliver Sartor |
|
209-211 |
Abarelix (Plenaxis™): A Gonadotropin-Releasing Hormone Antagonist for Medical Castration in Patients with Advanced Prostate Cancer G. Kesava Reddy, Vinay K. Jain, Oliver Sartor |
|
Addendum | ||
212 |
Improved Survival Benefit of Autologous Dendritic Cell–Based Vaccine for Hormone Refractory Prostate Cancer: A Retrospective Subset Analysis of the D9901 Trial Nancy Price, Oliver Sartor |
|
Comprehensive Reviews | ||
213-219 |
An Evaluation of Bicalutamide in the Treatment of Prostate Cancer Paul F. Schellhammer, John W. Davis |
|
220-227 |
Biochemical Recurrence and Survival Prediction Models for the Management of Clinically Localized Prostate Cancer Ashutosh Tewari, Eduard J. Gamito, E. David Crawford, Mani Menon |
|
228-235 |
Does Finasteride Alter the Pathology of the Prostate and Cancer Grading? David G. Bostwick, Junqi Qian, Francisco Civantos, Claus G. Roehrborn, Rodolfo Montironi |
|
Original Contribution | ||
236-240 |
Geriatric Assessment in Elderly Patients with Prostate Cancer Catherine Terret, Gilles Albrand, Jean Pierre Droz |
|
Current Trial | ||
241-243 |
A Phase I Study of Oral CC-5013 (Lenalidomide, Revlimid™), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer Tanyifor M. Tohnya, Sylvia S.W. Ng, William L. Dahut, John J. Wright, Philip M. Arlen, James L. Gulley, Catherine Parker, Jerome Zeldis, William D. Figg |
|